UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

29 Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Read More Share:

Nov

27 UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Read More Share:

Nov

17 Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Read More Share:

Nov

14 UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Nov

11 Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Read More Share:

Nov

10 UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Read More Share:

Nov

09 Advancing Rheumatic Disease Treatment

Read More Share:

Nov

06 Partnering with Caregivers to Advance the Ecosystem of Care for Rare Epilepsies

Read More Share:

Nov

01 UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:

Oct

31 NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Read More Share:

Categories

Archives

Nov

29

Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Nov

27

UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Nov

17

Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Nov

11

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Nov

10

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Nov

09

Advancing Rheumatic Disease Treatment

Nov

06

Partnering with Caregivers to Advance the Ecosystem of Care for Rare Epilepsies

Nov

01

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Oct

31

NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Nov

29

Delivering Meaningful and Accessible Innovation for People Living with Severe Diseases

Nov

27

UCB's Commitment to Diversity, Equity, and Inclusion: Partnering at AES for a Better Future

Nov

17

Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate

Nov

14

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Nov

11

Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

Nov

10

UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

Nov

09

Advancing Rheumatic Disease Treatment

Nov

06

Partnering with Caregivers to Advance the Ecosystem of Care for Rare Epilepsies

Nov

01

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Oct

31

NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact